Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1368 of 5804
-
Triple therapy targets tough brain metastases in lung cancer
Disease control Recruiting nowThis phase I study aims to investigate the safety and efficacy of whole brain low dose radiotherapy (WB-LDRT) combined with ICI and intrathecal chemotherapy for treatment of refractory meningeal metastasis of lung cancer.
Phase: PHASE1 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New study tests brain games and nerve zap to clear long COVID fog and get people back to work
Symptom relief Recruiting nowThis study will compare two approaches to cognitive rehabilitation in adults with long COVID with persistent, mild to moderate, cognitive impairment. One approach will feature (A) web-based computer "games" that trains how quickly individuals process information that they receive…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Promising drug targets rare chest cancers in new trial
Disease control Recruiting nowThe goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therapy. The main question it aims to answer is: • What is the overall response rate…
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Massive trial aims to outsmart superbugs in blood infections
Disease control Recruiting nowBALANCE+ is a perpetual multiple domain randomized controlled platform trial to evaluate various treatment strategies for Gram-negative bloodstream infections (GN BSIs). Each domain addresses critical questions in the management of GN BSIs, aiming to refine treatment strategies, …
Phase: NA • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Flu shot may calm artery inflammation after heart attack, new trial hopes to prove
Disease control Recruiting nowThe goal of this randomized, double-blind, placebo-controlled clinical trial is to investigate the immunological effects of influenza vaccination outside of the influenza season on arterial inflammation in patients with a recent acute myocardial infarction (AMI). The primary obje…
Phase: PHASE4 • Sponsor: Region Örebro County • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New heart ablation tech tracked in 10,000-Patient registry
Disease control ENROLLING_BY_INVITATIONThe DISRUPT-AF Registry is an observational, prospective, multi-center, non-randomized, real-world registry designed to obtain clinical experience with the Farapulse Pulsed Field Ablation System for the treatment of atrial fibrillation (AF).
Sponsor: Heart Rhythm Clinical and Research Solutions, LLC • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could a common gout drug help heart failure patients breathe easier?
Symptom relief Recruiting nowThe purpose of this research study is to determine the effectiveness of low dose colchicine (LoDoCo) on measures of exercise capacity, physical function, frailty, and quality of life, among patients with heart failure with chronic stable preserved ejection fraction (HFpEF) and sy…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Can smart monitoring keep heart patients out of the hospital?
Disease control OngoingThe goal of this study is to create a digital platform for managing patients with chronic heart failure, those with long-term ventricular assistance, or heart transplant recipients. This platform aims to help doctors make clinical decisions and change treatments based on continuo…
Phase: NA • Sponsor: Puerta de Hierro University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New pill shows promise in slowing lung scarring disease
Disease control CompletedThis is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once da…
Phase: PHASE2 • Sponsor: GRI Bio Operations, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug aims to protect transplanted kidneys
Disease control Recruiting nowEFFEKTOR is a vanguard, multicenter, phase 2 randomized, double blinded, placebo controlled clinical trial to determine the feasibility, tolerability, safety, and efficacy of finerenone in kidney transplant recipients (KTRs). One hundred fifty (150) KTRs will be randomized in a 2…
Phase: PHASE2 • Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Can a common MS drug help people with a rare nerve disease walk better?
Disease control OngoingThe goal of this clinical trial is to determine if dimethyl fumarate is effective in treating motor problems in adults with Adrenomyeloneuropathy. The trial will also assess the safety of dimethyl fumarate and explore the molecular mechanisms underlying the disease. The primary q…
Phase: PHASE2, PHASE3 • Sponsor: Pujol, Aurora, M.D. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a common blood pressure pill fight prostate cancer?
Disease control Recruiting nowThe goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficacy will also be gathered.
Phase: PHASE1 • Sponsor: Tyler J Curiel • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Sleep apnea treatment may shield aging brains from memory loss
Knowledge-focused Recruiting nowThe Effects of Successful OSA TreatmENT on Memory and AD BIomarkers in Older AduLts (ESSENTIAL) study is a 5-year, multicenter randomized open-label trial that will screen 400 cognitively normal older adults recruited from well-established sleep clinics at 4 academic medical cent…
Phase: NA • Sponsor: California Pacific Medical Center Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Could less be more? new trial tests lighter hormone therapy for prostate cancer
Disease control Recruiting nowThis phase II trial tests how well risk based de-escalated hormone therapy (i.e., fewer treatments) with radiation works in treating patients with prostate cancer. Androgen deprivation therapy (ADT), such as gonadotropin-releasing hormone analogs (LHRH) and abiraterone acetate (Z…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New hope for Hard-to-Treat cancers? early trial launches for BHV-1510
Disease control Recruiting nowThis is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
Phase: PHASE1, PHASE2 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Stroke recovery at home: brain training may cut dementia risk
Disease control CompletedThe goal of this 2-year, prospective, single-blind randomized clinical trial is to investigate: the efficacy in reducing the risk of cognitive impairment 6 months after stroke; the generalizability of cognitive reinforcement to real life, such as activities of daily living and qu…
Phase: NA • Sponsor: University of Florence • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Smart immune cells take aim at tough blood cancers
Disease control OngoingThis is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
Phase: PHASE1 • Sponsor: Senti Biosciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug hope for myelofibrosis patients with low platelets
Disease control Recruiting nowThe main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters w…
Phase: PHASE2 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New RNA drug aims to reverse liver damage in NASH patients
Disease control OngoingHuman genetic studies have shown that loss of function (LOF) mutations in HSD17β13 gene have a protective effect on the progression of alcohol-related and non-alcohol-related liver diseases, such as NASH, without significant adverse phenotypes. VSA006 is a siRNA drug targeting H…
Phase: PHASE2 • Sponsor: Visirna Therapeutics HK Limited • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Online course aims to boost mental health for teens leaving foster care
Disease control OngoingThis study will deploy a scalable secondary prevention program that leverages existing foster youth transition services to improve mental health functioning and service use before and after exiting foster care. Our short-term objective is to remotely test a group intervention cal…
Phase: NA • Sponsor: Portland State University • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC